A Prospective, Single-arm Study on Nimotuzumab Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced High-risk Squamous Cell Carcinoma of the Cervix
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CC11
- 17 Jan 2025 New trial record